Dr Fiona Sewell

Position

Head of Toxicology

Email address

fiona.sewell@nc3rs.org.uk


Fiona leads our programmes on toxicology and regulatory sciences focusing on human health effects. She is a member of the Science and Technology Group.

View Fiona's Office-led projects

External Roles

  • BTS exec committee

NC3Rs publications

Prior H, Haworth R, Labram B, Roberts R, Sewell F and Wolfreys A (2020). Justification for species selection for pharmaceutical toxicity studies. Toxicology Research (in press).

Sewell F, Kimber I, Boobis AR. (2020). Use of the kinetically-derived maximum dose: Opportunities for delivering 3Rs benefits. Regulatory Toxicology and Pharmacology 116: 104734. doi:10.1016/j.yrtph.2020.104734

Prior H, Baldrick P, Beken S, Booler H, Bower N, Brooker P, Brown P, Burlinson B, Burns-Naas L, Casey W, Chapman M, Clarke D, de Haan L, Doehr O, Downes N, Flaherty M, Gellatly N, Gry-Moesgaard S, Harris J, Holbrook M, Hui J, Jones D, Jones K, Kedar H, Mahl A, Manninen A, McGuire A, Mortimer-Cassen E, Peraza M, Pugsley M, Richard J, Roberts R, Roosen W, Rothfuss A, Schoenmakers A, Sewell F, Weaver R, Weir L, Wolfreys A and Kimber I (2020).  Opportunities for use of one species for longer-term toxicology testing during drug development: a cross-industry evaluation.  Regulatory Toxicology and Pharmacology 113: 104624. doi: 10.1016/j.yrtph.2020.104624.

Gellatly N and Sewell F (2019). Regulatory acceptance of in silico approaches for the safety assessment of cosmetic-related substances. Computational Toxicology 11: 82-89  DOI: 10.1016/j. comtox.2019.03.003.

Prior H, Casey W, Kimber I, Whelan M, Sewell F (2019). Reflections on the progress towards non-animal methods for acute toxicity testing of chemicals.  Regulatory Toxicology and Pharmacology 102: 30-33. doi: 10.1016/j.yrtph.2018.12.008.  

Sewell F, Ragan I, Indans I, Marczylo T, Stallard N, Griffiths D, Holmes T, Smith P and Horgan G (2018). An evaluation of the fixed concentration procedure for assessment of acute inhalation toxicity. Regulatory Toxicology and Pharmacology 94: 22-32. DOI: 10.1016/j.yrtph.2018.01.001.

Sewell F, Gellatly N, Beaumont M, Burden N, Currie R, de Haan L, Hutchinson TH, Jacobs M, Mahony C, Malcomber I, Mehta J, Whale G, Kimber I (2018). The future trajectory of adverse outcome pathways: a commentary. Archives of Toxicology 92(4): 1657-1661. DOI: 10.1007/s00204-018-2183-2.

Prior H, Sewell F, Stewart J (2017). Overview of 3Rs opportunities in drug discovery and development using non-human primates. Drug Discovery Today: Disease Models. 23: 11-16. doi: 10.1016/j.ddmod.2017.11.005

Sewell F, Doe J, Gellatly N, Ragan I, Burden N (2017). Steps towards the international regulatory acceptance of non-animal methodology in safety assessment. Regulatory Toxicology and Pharmacology 89: 50-56. DOI: 10.1016/j.yrtph.2017.07.001.

Sewell F, Aggarwal M, Bachler G, Broadmeadow A, Gellatly N, Moore E, Robinson S, Rooseboom M, Stevens A, Terry C, Burden N (2017). The current status of exposure-driven approaches for chemical safety assessment: A cross-sector perspective. Toxicology 389: 109-117. DOI: 10.1016/j. tox.2017.07.018.

Sewell F, Chapman K, Couch J, Dempster M, Heidel S, Loberg L, Maier C, Maclachlan TK, Todd M, van der Laan JW (2017). Challenges and opportunities for the future use of monoclonal antibody development: improving safety assessment and reducing animal use. MAbs 9(5): 742-755. DOI: 10.1080/19420862.2017.1324376.

Sewell F, Edwards J, Prior H, Robinson S (2016). Opportunities to apply the 3Rs in safety assessment programs. Institute for Laboratory Animal Research Journal. 57(2): 234-245. DOI: 10.1093/ilar/ilw024.

Sewell F, Ragan I, Marczylo T, Anderson B, Braun A, Casey W, Dennison N, Griffiths D, Guest R, Holmes T, van Huygevoort T, Indans I, Kenny T, Kojima H, Lee K, Prieto P, Smith P, Smedley J, Stokes WS, Wnorowski G, Horgan G (2015) A global initiative to refine acute inhalation studies through the use of 'evident toxicity' as an endpoint: Towards adoption of the fixed concentration procedure.  Regulatory Toxicology Pharmacology. 73(3):770-9. doi:10.1016/j.yrtph.2015.10.018.

Sewell F, Burden N, Chapman K, Robinson V. (2015). Pioneering Better Science through the 3Rs: An Introduction to the National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs). Journal of the American Association for Laboratory Animal Science 54(2):198-208. No doi, click to view.

Sewell F, Burden N, Chapman K (2015). Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches? PLoS Biology 13(5):e1002156 doi:10.1371/journal.pbio.1002156

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A,DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E,Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D. (2014). Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. Regulatory Toxicology and Pharmacology.70(1):413-29. doi:10.1016/j.yrtph.2014.07.018

For additional publications, see Fiona's ResearchGate profile.

Qualifications

UK and European Registered Toxicologist (ERT)
Accredited since 2019

PhD, Molecular Biology 
University of Leeds, 2005 - 2009
Therapeutic targeting of Fibroblast Growth Factor Receptor 3 (FGFR3) in urothelial cell carcinoma.